The shadow of generic competition has long loomed over copyright’s famous drug, Viagra, raising questions about the outlook of similar medicinal holdings. While early periods saw significant gains, the patent expiration has opened the path for discounted alternatives, possibly lowering earnings and posing a genuine risk for knockoff shareholders